Today
-0.82%
5 Days
-1.22%
1 Month
+1.53%
6 Months
+100.83%
Year to Date
+78.24%
1 Year
+59.17%
• Amgen's growth is driven by its metabolic disease pipeline and obesity candidate progress. • Robust oncology and inflammation sales support the company's updated revenue outlook. • Technical indicators show a neutral market signal with a bearish overall sentiment index.
• Positive clinical trial outcomes for Skyrizi and Rinvoq bolster AbbVie’s post-Humira growth strategy. • Institutional investors favor AbbVie for its robust dividend profile and resilient cash flows. • Investment banks recently raised long-term forecasts citing improved margins and reduced pricing concerns.
• Merck shares rose due to oncology pipeline progress and portfolio diversification. • Analysts increased price targets following strong vaccine and animal health performance. • Technical indicators show a neutral market signal with an RSI of 51.947.


| Shareholders | Proportion |
|---|---|
| Apeiron Investment Group Ltd | 15.00% |
| Vanguard Capital Management, LLC | 3.19% |
| Feilding-Mellen (Cosmo) | 2.08% |
| Adage Capital Management, L.P. | 1.92% |
| Shareholder Types | Proportion |
|---|---|
| Family Office | 15.07% |
| Investment Advisor | 9.87% |
| Hedge Fund | 6.24% |
| Investment Advisor/Hedge Fund | 4.50% |
Related Instruments
Popular Instruments